Kineta 관리

Name: S&P 글로벌 시장 인텔리전스에 기반한 금융 인사이트
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	2yrs
이사회 평균 재임 기간	2yrs

최근 관리 업데이트

Recent updates

CEO

Kineta 에는 CEO가 없거나 그에 대한 데이터가 없습니다.

리더십 팀

이름	위치	테뉴어	보상	소유권
Craig Philips	President & Secretary	2yrs	US$993.40k	0.78% $ 72.5k
Keith Baker	Chief Financial Officer	2yrs	US$813.69k	0.14% $ 12.8k
Thierry Guillaudeux	Chief Scientific Officer	2yrs	데이터 없음	0.18% $ 16.5k
Gary Gentges	Executive Vice President of Corporate Development	no data	데이터 없음	데이터 없음
Pauline Kenny	Advisor	less than a year	US$741.73k	0.15% $ 14.0k

2.0yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: KANT 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
David Arkowitz	Independent Director	2yrs	US$141.55k	0.023% $ 2.1k
Kimberlee Drapkin	Independent Director	1.5yrs	US$69.85k	0% $ 0
Shawn P. Iadonato	Chairman of the Board	2yrs	US$1.28m	5.61% $ 522.9k
Raymond Bartoszek	Independent Director	2yrs	US$86.37k	14.68% $ 1.4m
Marion Foote	Independent Director	2yrs	US$90.12k	1.17% $ 108.8k
Scott Dylla	Independent Director	1.5yrs	US$66.10k	0.033% $ 3.0k
Richard Peters	Lead Independent Director	2yrs	US$148.18k	0.73% $ 68.4k
Lisa Coussens	Member of Scientific Advisory Board	4.7yrs	데이터 없음	데이터 없음
Patricia LoRusso	Member of Scientific Advisory Board	4.7yrs	데이터 없음	데이터 없음
Michael Curran	Member of Scientific Advisory Board	4.7yrs	데이터 없음	데이터 없음
Evan Yu	Member of Scientific Advisory Board	1.8yrs	데이터 없음	데이터 없음
Myriam Chalabi	Member of Scientific Advisory Board	1.8yrs	데이터 없음	데이터 없음

2.0yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: KANT 의 이사회는 경험(평균 재직 기간 2 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Kineta 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

High number of new and inexperienced directors

Kineta, Inc., Annual General Meeting, Jun 21, 2024

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Announces Board Appointments

No independent directors

Recent updates

TuHURA Biosciences, Inc. (NasdaqCM:HURA) entered into a definitive agreement to acquire Kineta, Inc.

Kineta, Inc. Updates KVA12123 Clinical Results from Ongoing Phase 1/2 Vista101 Study at Society for Immunotherapy of Cancer (2024)

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Kineta, Inc. Announces the Extension of the TuHura Biosciences Exclusivity and Right of First Offer Agreement for KVA12123

Kineta, Inc.(OTCPK:KANT) dropped from S&P TMI Index

Nasdaq Suspends Trading of Kineta's Common Stock Following Denial of Continued Listing Request, Effective September 19, 2024 and to File Form 25-NSE with the Securities and Exchange Commission

Kineta, Inc.(OTCPK:KANT) dropped from NASDAQ Composite Index

Nasdaq Listing Qualifications Staff Denies Kineta, Inc.'s Request for Continued Listing on the Nasdaq Capital Market

Nasdaq Listing Qualifications Staff Denies Kineta, Inc.'s Request for Continued Listing on the Nasdaq Capital Market

Kineta, Inc. Re Opens Enrollment for the Vista-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

Kineta Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding No Longer Complies with the Requirement Under Nasdaq Listing Rule 5550(b)(1)

High number of new and inexperienced directors

Kineta, Inc., Annual General Meeting, Jun 21, 2024

Kineta Receives Written Notice from Nasdaq Regarding Non-Compliance Minimum Closing Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial

Kineta, Inc. Announces an Update on Its Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating Kva12123

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Announces Restructuring and Workforce Reduction

Kineta, Inc. Announces Update on Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Tumor Activity

Kineta, Inc. Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s 38th Annual Meeting

Kineta, Inc. Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Advanced Solid Tumors

Kineta, Inc. Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 Vista-101 Clinical Trial

New major risk - Share price stability

Kineta Regains Compliance with Nasdaq Listing Rules

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Kineta, Inc. Announces Board Appointments

Third quarter 2022 earnings released

No independent directors

Kineta, Inc. completed the acquisition of Yumanity Therapeutics, Inc. (NasdaqCM:YMTX) from a group of shareholders in a reverse merger transaction.

CEO

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령